VERTEX PHARMACEUTICALS INC / MA — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Vertex agreed to acquire Crinetics Pharmaceuticals for $85.00/share, totaling ~$10.0B equity value (~$8.8B net of cash), expected to close Q3 2026. Q2 2026 revenue reached $3.33B (+12% YoY); Vertex raised full-year 2026 revenue guidance to $13.1–$13.2B from $12.95–$13.1B. The Crinetics deal adds rare endocrine diseases as Vertex's fifth therapeutic pillar; updated 2026 guidance excludes Crinetics impact and will be provided post-close.
Why this rating
Crinetics deal (~$10B) is ~9% of Vertex's $113.4B market cap—material but not transformational for a diversified biotech. Revenue beat and guidance raise are modest (+$150–200M annualized). Positive catalysts offset by deal execution risk and integration uncertainty.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.